Skip to main content
Theralase Technologies Inc. logo

Theralase Technologies Inc. — Investor Relations & Filings

Ticker · TLT ISIN · CA88337V1004 LEI · 529900NI3Y8GLE2IBF28 TSXV Manufacturing
Open in API
Filings indexed 698 across all filing types
Latest filing 2024-03-27 Annual Report
Country CA Canada
Listing TSXV TLT

About Theralase Technologies Inc.

https://theralase.com/

Theralase Technologies Inc. designs, develops, manufactures, and markets patented laser technology platforms for both bio-stimulative and bio-destructive medical applications. The company operates two core divisions. The first is Cool Laser Therapy (CLT), which utilizes proprietary super-pulsed laser systems for therapeutic purposes, focusing on pain management, inflammation reduction, tissue repair, and the effective elimination of chronic knee pain. The second is Anti-Cancer Therapy (ACT), which employs patented light-activated Photo Dynamic Compounds (PDCs) combined with laser technology for destructive applications, specifically targeting the safe and effective destruction of cancer, bacteria, and viruses.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Annual Report Classification · 95% confidence The document is a press release from Theralase Technologies Inc. dated March 27, 2024, announcing the release of their audited annual consolidated 2023 financial statements. It includes detailed financial data for the year ended December 31, 2023, such as revenue, expenses, net loss, and operational highlights. The document also discusses clinical study updates, private placements (financing activities), and future plans. The presence of detailed financial statements and operational data for a full fiscal year indicates this is an Annual Report or equivalent comprehensive financial disclosure. However, the document is titled as a press release and includes a conference call announcement for discussing the financial results, which is typical for an Earnings Release. Yet, the financial data is comprehensive and audited annual financial statements are mentioned, which aligns more with an Annual Report (10-K) rather than a brief Earnings Release (ER). The document also includes significant operational and clinical data, which is common in annual reports for clinical-stage companies. The document length (15,000 characters) and detailed financial tables confirm it is not a brief announcement or a simple earnings summary. Therefore, the best classification is Annual Report (10-K). FY 2023
2024-03-27 English
News release - English.pdf
Regulatory Filings
2024-03-26 English
Material change report - English.pdf
Regulatory Filings
2024-03-01 English
Report of exempt distribution (45-106F1).pdf
Regulatory Filings Classification · 95% confidence The document is titled 'Form 45-106F1 Report of Exempt Distribution' and contains detailed information about a securities distribution under an exemption, including issuer details, distribution dates, purchaser information, compensation related to the distribution, and regulatory references to National Instrument 45-106. This form is a regulatory filing used in Canada to report exempt distributions of securities. It is not a financial report like an annual or quarterly report, nor is it an earnings release or management discussion. It is a specific regulatory filing related to securities distribution compliance. Therefore, the most appropriate classification is Regulatory Filings (RNS). The document length is substantial and contains detailed data, confirming it is not a mere announcement or certification but a full regulatory report.
2024-02-14 English
News release - English.pdf
Regulatory Filings Classification · 85% confidence The document is a press release announcing the donation of laser therapy technology by Theralase Technologies Inc. to aid research and development of a treatment for Parkinson's Disease. It contains no financial data, no regulatory filings, no shareholder information, no earnings or financial results, and no mention of any report being attached or published. The content is focused on a corporate announcement related to research collaboration and technology donation, which is typical of a Capital/Financing Update or general corporate news. However, there is no mention of fundraising, financing activities, or capital structure changes. It is not a regulatory filing or report publication announcement. Given the nature of the announcement as a corporate update on a technology donation and research collaboration, the best fitting category is Regulatory Filings (RNS) as a general corporate announcement that does not fit other specific categories.
2024-02-12 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing the appointment of Dr. Michael Jewett as an independent consultant to assist in completing enrollment in a Phase II clinical study for a pharmaceutical company. It discusses clinical study progress, patient enrollment targets, and forward-looking statements about the company's development plans and regulatory approval prospects. There are no financial statements, detailed financial performance data, or regulatory filings such as annual or quarterly reports. The content is focused on a corporate update related to clinical trial progress and management consulting engagement rather than financial results or governance changes. Therefore, this document fits best as a Regulatory Filing (RNS) since it is a general corporate announcement that does not fit into more specific categories like Annual Report, Earnings Release, or Management Reports.
2024-02-08 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.